Tokai appoints CMO and VP of medical development
This article was originally published in Scrip
Tokai, a biopharmaceutical firm specialising in prostrate cancer treatments, has appointed Adrian M. Senderowicz as its chief medical officer and vice-president of medical development. Dr Senderowicz has previously served as medical director of oncology clinical development at AstraZeneca. In this role he oversaw the US FDA approval of Caprelsa (vandetanib) for advanced medullary thyroid carcinoma. Before joining AstraZeneca, he held various senior positions at the FDA Division of Oncology Drug Products in the Center for Drug Evaluation and Research. Tokai says that Dr Senderowicz brings valuable expertise to the development of its lead candidate, galeterone (TOK-001), which recently won an FDA fast-track designation from for metastatic castration-resistant prostate cancer.
You may also be interested in...
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.
Brazil’s pharmaceutical industry has welcomed the election of medicines regulator ANVISA to the management committee of the International Council for Harmonization.